Management of advanced primary urethral carcinomas

Farshid Dayyani, Karen Hoffman, Patricia Eifel, Charles Guo, Raghu Vikram, Lance C. Pagliaro, Curtis Pettaway

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Primary urethral carcinoma (PUC) is a rare malignancy accounting for <1% of genitourinary cancers, with a predilection for men and African-Americans. The sites and histology of urethral carcinoma vary by gender and anatomical location. Squamous cell carcinoma is most common among both genders but adenocarcinomas are noted in 15-35% of cases among women. Obstructive or irritative symptoms and haematuria are common modes of presentation. Clinical evaluation includes cystourethroscopy with biopsy and examination under anaesthesia. Magnetic resonance imaging provides a highly effective method to image the primary tumour while defbox drawings light down and leftning the potential involvement of surrounding structures. Most tumours are localised, with regional metastases to nodal sites seen in up to 30% of cases in both genders, while distant metastases at presentation are rare (0-6%), but occur in up to 40% of cases with recurrent disease. Among men, the two most important prognostic factors are disease location and stage. Low-stage tumours (T1-2) and tumours involving the fossa navicularis or the penile urethra have a better prognosis than higher stage tumours (>T2 or N+) and lesions involving the bulbomembranous urethra. In women, in addition to stage and location, the size of the tumour has also prognostic implications. While surgery and radiation therapy (RT) are of benefit in early stage disease, advanced stage PUC requires multimodal treatment strategies to optimise local control and survival. These include induction chemotherapy followed by surgery or RT and concurrent chemoradiation with or without surgery. The latter strategy has been used successfully to treat other human papillomavirus-related cancers of the vagina, cervix and anus and may be of value in achieving organ preservation. Given the rarity of PUC, prospective multi-institutional studies are needed to better define the optimal treatment approach for this disease entity.

Original languageEnglish (US)
Pages (from-to)25-31
Number of pages7
JournalBJU International
Volume114
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Carcinoma
Radiotherapy
Vaginal Neoplasms
Anus Neoplasms
Organ Preservation
Combined Modality Therapy
Induction Chemotherapy
Urethra
Uterine Cervical Neoplasms
Neoplasms
Survival
Therapeutics

Keywords

  • diagnosis
  • multimodal management
  • prognosis
  • urethral carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Dayyani, F., Hoffman, K., Eifel, P., Guo, C., Vikram, R., Pagliaro, L. C., & Pettaway, C. (2014). Management of advanced primary urethral carcinomas. BJU International, 114(1), 25-31. https://doi.org/10.1111/bju.12630

Management of advanced primary urethral carcinomas. / Dayyani, Farshid; Hoffman, Karen; Eifel, Patricia; Guo, Charles; Vikram, Raghu; Pagliaro, Lance C.; Pettaway, Curtis.

In: BJU International, Vol. 114, No. 1, 2014, p. 25-31.

Research output: Contribution to journalReview article

Dayyani, F, Hoffman, K, Eifel, P, Guo, C, Vikram, R, Pagliaro, LC & Pettaway, C 2014, 'Management of advanced primary urethral carcinomas', BJU International, vol. 114, no. 1, pp. 25-31. https://doi.org/10.1111/bju.12630
Dayyani F, Hoffman K, Eifel P, Guo C, Vikram R, Pagliaro LC et al. Management of advanced primary urethral carcinomas. BJU International. 2014;114(1):25-31. https://doi.org/10.1111/bju.12630
Dayyani, Farshid ; Hoffman, Karen ; Eifel, Patricia ; Guo, Charles ; Vikram, Raghu ; Pagliaro, Lance C. ; Pettaway, Curtis. / Management of advanced primary urethral carcinomas. In: BJU International. 2014 ; Vol. 114, No. 1. pp. 25-31.
@article{806be41e6c9240d288d313761f88b7e0,
title = "Management of advanced primary urethral carcinomas",
abstract = "Primary urethral carcinoma (PUC) is a rare malignancy accounting for <1{\%} of genitourinary cancers, with a predilection for men and African-Americans. The sites and histology of urethral carcinoma vary by gender and anatomical location. Squamous cell carcinoma is most common among both genders but adenocarcinomas are noted in 15-35{\%} of cases among women. Obstructive or irritative symptoms and haematuria are common modes of presentation. Clinical evaluation includes cystourethroscopy with biopsy and examination under anaesthesia. Magnetic resonance imaging provides a highly effective method to image the primary tumour while defbox drawings light down and leftning the potential involvement of surrounding structures. Most tumours are localised, with regional metastases to nodal sites seen in up to 30{\%} of cases in both genders, while distant metastases at presentation are rare (0-6{\%}), but occur in up to 40{\%} of cases with recurrent disease. Among men, the two most important prognostic factors are disease location and stage. Low-stage tumours (T1-2) and tumours involving the fossa navicularis or the penile urethra have a better prognosis than higher stage tumours (>T2 or N+) and lesions involving the bulbomembranous urethra. In women, in addition to stage and location, the size of the tumour has also prognostic implications. While surgery and radiation therapy (RT) are of benefit in early stage disease, advanced stage PUC requires multimodal treatment strategies to optimise local control and survival. These include induction chemotherapy followed by surgery or RT and concurrent chemoradiation with or without surgery. The latter strategy has been used successfully to treat other human papillomavirus-related cancers of the vagina, cervix and anus and may be of value in achieving organ preservation. Given the rarity of PUC, prospective multi-institutional studies are needed to better define the optimal treatment approach for this disease entity.",
keywords = "diagnosis, multimodal management, prognosis, urethral carcinoma",
author = "Farshid Dayyani and Karen Hoffman and Patricia Eifel and Charles Guo and Raghu Vikram and Pagliaro, {Lance C.} and Curtis Pettaway",
year = "2014",
doi = "10.1111/bju.12630",
language = "English (US)",
volume = "114",
pages = "25--31",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Management of advanced primary urethral carcinomas

AU - Dayyani, Farshid

AU - Hoffman, Karen

AU - Eifel, Patricia

AU - Guo, Charles

AU - Vikram, Raghu

AU - Pagliaro, Lance C.

AU - Pettaway, Curtis

PY - 2014

Y1 - 2014

N2 - Primary urethral carcinoma (PUC) is a rare malignancy accounting for <1% of genitourinary cancers, with a predilection for men and African-Americans. The sites and histology of urethral carcinoma vary by gender and anatomical location. Squamous cell carcinoma is most common among both genders but adenocarcinomas are noted in 15-35% of cases among women. Obstructive or irritative symptoms and haematuria are common modes of presentation. Clinical evaluation includes cystourethroscopy with biopsy and examination under anaesthesia. Magnetic resonance imaging provides a highly effective method to image the primary tumour while defbox drawings light down and leftning the potential involvement of surrounding structures. Most tumours are localised, with regional metastases to nodal sites seen in up to 30% of cases in both genders, while distant metastases at presentation are rare (0-6%), but occur in up to 40% of cases with recurrent disease. Among men, the two most important prognostic factors are disease location and stage. Low-stage tumours (T1-2) and tumours involving the fossa navicularis or the penile urethra have a better prognosis than higher stage tumours (>T2 or N+) and lesions involving the bulbomembranous urethra. In women, in addition to stage and location, the size of the tumour has also prognostic implications. While surgery and radiation therapy (RT) are of benefit in early stage disease, advanced stage PUC requires multimodal treatment strategies to optimise local control and survival. These include induction chemotherapy followed by surgery or RT and concurrent chemoradiation with or without surgery. The latter strategy has been used successfully to treat other human papillomavirus-related cancers of the vagina, cervix and anus and may be of value in achieving organ preservation. Given the rarity of PUC, prospective multi-institutional studies are needed to better define the optimal treatment approach for this disease entity.

AB - Primary urethral carcinoma (PUC) is a rare malignancy accounting for <1% of genitourinary cancers, with a predilection for men and African-Americans. The sites and histology of urethral carcinoma vary by gender and anatomical location. Squamous cell carcinoma is most common among both genders but adenocarcinomas are noted in 15-35% of cases among women. Obstructive or irritative symptoms and haematuria are common modes of presentation. Clinical evaluation includes cystourethroscopy with biopsy and examination under anaesthesia. Magnetic resonance imaging provides a highly effective method to image the primary tumour while defbox drawings light down and leftning the potential involvement of surrounding structures. Most tumours are localised, with regional metastases to nodal sites seen in up to 30% of cases in both genders, while distant metastases at presentation are rare (0-6%), but occur in up to 40% of cases with recurrent disease. Among men, the two most important prognostic factors are disease location and stage. Low-stage tumours (T1-2) and tumours involving the fossa navicularis or the penile urethra have a better prognosis than higher stage tumours (>T2 or N+) and lesions involving the bulbomembranous urethra. In women, in addition to stage and location, the size of the tumour has also prognostic implications. While surgery and radiation therapy (RT) are of benefit in early stage disease, advanced stage PUC requires multimodal treatment strategies to optimise local control and survival. These include induction chemotherapy followed by surgery or RT and concurrent chemoradiation with or without surgery. The latter strategy has been used successfully to treat other human papillomavirus-related cancers of the vagina, cervix and anus and may be of value in achieving organ preservation. Given the rarity of PUC, prospective multi-institutional studies are needed to better define the optimal treatment approach for this disease entity.

KW - diagnosis

KW - multimodal management

KW - prognosis

KW - urethral carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84903291554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903291554&partnerID=8YFLogxK

U2 - 10.1111/bju.12630

DO - 10.1111/bju.12630

M3 - Review article

C2 - 24447439

AN - SCOPUS:84903291554

VL - 114

SP - 25

EP - 31

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -